Navigation Links
Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic Resistance Published in Nature Biotechnology

VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ -- Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.

The paper, which highlights the work of Inimex and its co-founders Dr. Bob Hancock and Dr. Brett Finlay, shows that IDR-1 protected mice against Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) infections. With as little as one dose, IDR-1 increased the levels of key immune system fighter cells, which caused prolonged enhancement of the host immune system's response to these antibiotic-resistant pathogens. A key finding was that the product eradicated the infections without increasing the levels of pro-inflammatory cytokines that are typically present during the first stage of immunity.

"The body's immune system naturally possesses the tools to fight infections," said John North, president and chief executive officer of Inimex. "We're developing therapeutics that utilize this powerful innate response without the threat of a cytokine storm that can lead to sepsis."

Bob Hancock added: "The success of our product in controlling bacterial infection represents a novel approach at a time when antibiotic resistance is getting worse every day. With the decline of new antibiotic discovery, we desperately need new avenues of research for the treatment of super bugs."

Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) cause infections that antibiotics can no longer treat and account for more than 90,000 deaths each year in North America alone. Inimex's goal is to develop IDR products as a new line of defense against pathogens that seek out
'"/>




Page: 1 2

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/27/2008)...ionally Recognized Pediatric Heart Center at The C...s for Community to Complete Range of Care and ...Recruited Pediatric Cardiology Team Treats Every H...ewswire/ -- The Children,s Hospital at,Montefiore ...c heart,transplantation to the Bronx, following th...
(Date:8/26/2008)...SALEM, Ore., Aug. 26 /- The Oregon To...ity Care Customer Service Training Program,(Q Care...gon Q Care is a training program created to suppor...anced employee education. By emphasizing,the impor...ll equip,employees with tools and resources to bet...
(Date:8/26/2008)...INDIANAPOLIS, Aug. 26 /- Semafore Pha...Seventh International Congress on Targeted,Therapi...al antiangiogenic,activity of vascular-targeted PI... VEGF and Bv8 signaling., PI3K is part of a very ...as been shown to play a major role in cancer. Stud...
(Date:8/26/2008)...Study finds most patients can drive safely six wee...Aug. 26 /PRNewswire-USNewswire/ -- Six weeks follo...e so low that they are able to,get back behind the...gust,2008 issue of The Journal of Bone and Joint S...ergency brake time response in patients who underw...
Breaking Medicine Technology:Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 1Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 5MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 1MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 2MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 1CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 4Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 1Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 2
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: